Research ArticleCELL BIOLOGY

Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis

See allHide authors and affiliations

Science Advances  27 May 2020:
Vol. 6, no. 22, eaba3167
DOI: 10.1126/sciadv.aba3167

Article Information

vol. 6 no. 22

PubMed: 
Online ISSN: 
History: 
  • Received for publication November 22, 2019
  • Accepted for publication March 20, 2020
  • .

Author Information

  1. Xin Chang1,*,
  2. Lei Xing1,2,3,4,*,
  3. Yi Wang1,*,
  4. Chen-Xi Yang1,
  5. Yu-Jing He1,
  6. Tian-Jiao Zhou1,
  7. Xiang-Dong Gao2,
  8. Ling Li5,
  9. Hai-Ping Hao6, and
  10. Hu-Lin Jiang1,2,3,4,
  1. 1State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
  2. 2Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, China.
  3. 3Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China.
  4. 4Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing 210009, China.
  5. 5Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
  6. 6State Key Laboratory of Natural Medicines, Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
  1. Corresponding author. Email: hhp_770505{at}hotmail.com (H.-P.H.); jianghulin3{at}gmail.com (H.-L.J.)
  • * These authors contributed equally to this work.

Altmetric

Article usage

Article usage: to

AbstractFullPdf

Stay Connected to Science Advances

Navigate This Article